Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes

Smith U, Gale EAM (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699–1708

Wiesli P, Krayenbühl P, Uthoff H, Seifert B, Schmid C (2009) Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes. Diabetologia 52:1816–1819

Riddle MC, Rosenstock J, Gerich J (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080–3086

Hermansen K, Davies M, Derezinksi T, Martinez Ravn G, Clauson P, Home P (2006) A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29:1269–1274

Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M (2008) Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med 25:916–923

Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M et al (2006) Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49:442–451